Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples

(2016) Jutta K. Preiksaitis et al.   CLINICAL INFECTIOUS DISEASES

Commutability of the First World Health Organization International Standard for Human Cytomegalovirus

(2015) R. T. Hayden et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group

(2014) C Hutchison et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

(2014) Roy F. Chemaly et al.   NEW ENGLAND JOURNAL OF MEDICINE

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

(2013) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

(2012) Mohamed A Kharfan-Dabaja et al.   LANCET INFECTIOUS DISEASES

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

(2011) Paul D Griffiths et al.   LANCET

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

(2011) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development

(2009) V Miller   CLINICAL PHARMACOLOGY & THERAPEUTICS